In particular, although the effect of PI3KCA pathway activation as a mechanism of resistance to HER2-directed therapy in CRC has not been directly investigated, activating mutations of PI3KCA and decreased expression of PTEN have been identified as potential mechanisms of resistance to trastuzumab and lapatinib in breast cancer [43, 44]. This evidence concerns the gene ERBB2 and breast carcinoma.